Septerna, Inc.

Contributing Author

Recent Articles by Septerna, Inc.

Aug-27	Septerna to Participate in Upcoming Investor Conferences SEPN GlobeNewswire
Aug-21	Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases SEPN GlobeNewswire
Aug-11	Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results SEPN GlobeNewswire
May-29	Septerna to Present at Jefferies Global Healthcare Conference SEPN GlobeNewswire
May-15	Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results SEPN GlobeNewswire